Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration

Journal of Clinical Pharmacology

Volumn 50, Issue 11, 2010, Pages 1292-1300

  Salinger, David H ^a,f   Vicini, Paolo ^a,g   Blough, David K ^b,c   O'Donnell, Paul V ^b,d   Pawlikowski, Matthew A ^e   McCune, Jeannine S ^b,d  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center ^*  (Australia)

^d Fred Hutchinson Cancer Research Center   (United States)

^e SEATTLE CANCER CARE ALLIANCE   (United States)

^f AMGEN INC   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

busulfan; hematopoietic cell transplant; personalized medicine; pharmacokinetics; population pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; MELPHALAN; THYMOCYTE ANTIBODY;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; MALE; OUTPATIENT CARE; PLASMA CONCENTRATION-TIME CURVE; POPULATION MODEL; RETROSPECTIVE STUDY;

ADULT; AGED; AMBULATORY CARE FACILITIES; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BAYES THEOREM; BUSULFAN; COMPUTER SIMULATION; DRUG MONITORING; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 78449281203     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009357430     Document Type: Article

References (27)

1. Deeg HJ, Maris MB, Scott BL, et al. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia. 2006 ; 20: 1701-1705.
2. McCune JS, Gibbs JP, Slattery JT Plasma concentration monitoring of busulfan: does it improve clinical outcome ? Clin Pharmacokinet. 2000 ; 39: 155-165.
3. Andersson BS, Thall PF, Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002 ; 8: 477-485.
4. Geddes M., Kangarloo SB, Naveed F., et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant. 2008 ; 14: 220-228.
5. Russell JA, Tran HT, Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002 ; 8: 468-476.
6. Bornhauser M., Storer B., Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003 ; 102: 820-826.
7. de Lima M., Couriel D., Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 ; 104: 857-864.
8. Altman J., Venepalli N., Monreal J., et al. Oral busulfan and cyclophosphamide or IV busulfan and fludarabine for allogeneic HSCT in hematologic malignancies? Blood. 2006 ; 108 :abstract-2940.
9. Andersson BS, de Lima M., Thall PF, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008 ; 14: 672-684.
10. Kletzel M., Jacobsohn D., Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 ; 12: 472-479.
11. Naveed F., Kangarloo S., Chaudhry A., et al. Improving the pharmacokinetic analysis of the once daily IV busulfan regimen for allogeneic stem-cell transplants: a scientific method modification. Blood. 2006 ; 108 :abstract # 2941.
12. Field T., Perkins J., Alsina M., et al. Busulfan area-under-the-curve finding study within a busulfan/fludarabine (BuFlu) conditioning regimen before allogeneic hematopoietic cell transplantation (HCT). Blood. 2006 ; 108 :abstract # 2939.
13. Bullock JM, Smith PF, Booker BM, et al. Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 2006 ; 28: 62-66.
14. Bleyzac N., Souillet G., Magron P., et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001 ; 28: 743-751.
15. Nguyen L., Fuller D., Lennon S., et al. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004 ; 33: 979-987.
16. Nguyen L., Leger F., Lennon S., et al. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol. 2006 ; 57: 191-198.
17. Booth BP, Rahman A., Dagher R., et al. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. J Clin Pharmacol. 2007 ; 47: 101-111.
18. Vaughan WP, Carey D., Perry S., et al. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant. 2002 ; 8: 619-624.
19. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995 ; 16: 31-42.
20. Slattery JT, Risler LJ Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998 ; 20: 543-549.
21. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing ; 2007.
22. Callegari T., Caumo A., Cobelli C. Generalization of map estimation in SAAM II: validation against ADAPT II in a glucose model case study. Ann Biomed Eng. 2002 ; 30: 961-968.
23. Sheiner LB, Beal SL Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981 ; 9: 503-512. 24. Wahlby U., Jonsson EN, Karlsson MO Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001 ; 28: 231-252.
24. Madden T., de Lima M., Thapar N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007 ; 13: 56-64.
25. D'Argenio DZ Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Math Biosci. 1990 ; 99: 105-118.
26. Jelliffe RW, Schumitzky A., Van Guilder M., et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit. 1993 ; 15: 380-393.
27. Salinger DH, McCune JS, Blough DK, et al. Mean squared error as criterion for sampling schedule optimization for individual dose targeting in IV busulfan. PAGE. 2008 ; 17 :abstract 1413. http://www.page-meeting.org/?abstract= 1413.